These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

768 related items for PubMed ID: 16275807

  • 1. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
    Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE.
    Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
    [Abstract] [Full Text] [Related]

  • 2. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia.
    Lane HY, Lin CH, Huang YJ, Liao CH, Chang YC, Tsai GE.
    Int J Neuropsychopharmacol; 2010 May; 13(4):451-60. PubMed ID: 19887019
    [Abstract] [Full Text] [Related]

  • 3. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
    Weiser M, Heresco-Levy U, Davidson M, Javitt DC, Werbeloff N, Gershon AA, Abramovich Y, Amital D, Doron A, Konas S, Levkovitz Y, Liba D, Teitelbaum A, Mashiach M, Zimmerman Y.
    J Clin Psychiatry; 2012 Jun; 73(6):e728-34. PubMed ID: 22795211
    [Abstract] [Full Text] [Related]

  • 4. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.
    Lane HY, Huang CL, Wu PL, Liu YC, Chang YC, Lin PY, Chen PW, Tsai G.
    Biol Psychiatry; 2006 Sep 15; 60(6):645-9. PubMed ID: 16780811
    [Abstract] [Full Text] [Related]

  • 5. D-alanine added to antipsychotics for the treatment of schizophrenia.
    Tsai GE, Yang P, Chang YC, Chong MY.
    Biol Psychiatry; 2006 Feb 01; 59(3):230-4. PubMed ID: 16154544
    [Abstract] [Full Text] [Related]

  • 6. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
    Tsai G, Lane HY, Yang P, Chong MY, Lange N.
    Biol Psychiatry; 2004 Mar 01; 55(5):452-6. PubMed ID: 15023571
    [Abstract] [Full Text] [Related]

  • 7. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
    Lane HY, Lin CH, Green MF, Hellemann G, Huang CC, Chen PW, Tun R, Chang YC, Tsai GE.
    JAMA Psychiatry; 2013 Dec 01; 70(12):1267-75. PubMed ID: 24089054
    [Abstract] [Full Text] [Related]

  • 8. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.
    Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, Catinari S, Ermilov M.
    Biol Psychiatry; 2005 Mar 15; 57(6):577-85. PubMed ID: 15780844
    [Abstract] [Full Text] [Related]

  • 9. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
    Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT.
    Am J Psychiatry; 2007 Oct 15; 164(10):1593-602. PubMed ID: 17898352
    [Abstract] [Full Text] [Related]

  • 10. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
    Furukawa TA, Levine SZ, Tanaka S, Goldberg Y, Samara M, Davis JM, Cipriani A, Leucht S.
    JAMA Psychiatry; 2015 Jan 15; 72(1):14-21. PubMed ID: 25372935
    [Abstract] [Full Text] [Related]

  • 11. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
    Modabbernia A, Rezaei F, Salehi B, Jafarinia M, Ashrafi M, Tabrizi M, Hosseini SM, Tajdini M, Ghaleiha A, Akhondzadeh S.
    CNS Drugs; 2013 Jan 15; 27(1):57-65. PubMed ID: 23233269
    [Abstract] [Full Text] [Related]

  • 12. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.
    Usall J, López-Carrilero R, Iniesta R, Roca M, Caballero M, Rodriguez-Jimenez R, Oliveira C, Bernardo M, Corripio I, Sindreu SD, González Piqueras JC, Felipe AE, Fernandez de Corres B, Ibáñez A, Huerta R, Abordaje Síntomas Negativos Esquizofrenia Group.
    J Clin Psychiatry; 2014 Jun 15; 75(6):608-15. PubMed ID: 25004184
    [Abstract] [Full Text] [Related]

  • 13. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.
    Singh SP, Singh V.
    CNS Drugs; 2011 Oct 01; 25(10):859-85. PubMed ID: 21936588
    [Abstract] [Full Text] [Related]

  • 14. Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double-blind, randomized placebo-controlled trial.
    Ghajar A, Gholamian F, Tabatabei-Motlagh M, Afarideh M, Rezaei F, Ghazizadeh-Hashemi M, Akhondzadeh S.
    Hum Psychopharmacol; 2018 Jul 01; 33(4):e2662. PubMed ID: 29901250
    [Abstract] [Full Text] [Related]

  • 15. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR.
    Arch Gen Psychiatry; 2003 Jul 01; 60(7):681-90. PubMed ID: 12860772
    [Abstract] [Full Text] [Related]

  • 16. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.
    Kane JM, D'Souza DC, Patkar AA, Youakim JM, Tiller JM, Yang R, Keefe RS.
    J Clin Psychiatry; 2010 Nov 01; 71(11):1475-81. PubMed ID: 20816042
    [Abstract] [Full Text] [Related]

  • 17. ALDH2 polymorphism, associated with attenuating negative symptoms in patients with schizophrenia treated with add-on dextromethorphan.
    Lee SY, Chen SL, Chang YH, Chen PS, Huang SY, Tzeng NS, Wang LJ, Lee IH, Wang TY, Chen KC, Yang YK, Hong JS, Lu RB.
    J Psychiatr Res; 2015 Oct 01; 69():50-6. PubMed ID: 26343594
    [Abstract] [Full Text] [Related]

  • 18. Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial.
    Lin CY, Liang SY, Chang YC, Ting SY, Kao CL, Wu YH, Tsai GE, Lane HY.
    World J Biol Psychiatry; 2017 Aug 01; 18(5):357-368. PubMed ID: 26691576
    [Abstract] [Full Text] [Related]

  • 19. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
    Hosseini SM, Farokhnia M, Rezaei F, Gougol A, Yekehtaz H, Iranpour N, Salehi B, Tabrizi M, Tajdini M, Ghaleiha A, Akhondzadeh S.
    Eur Neuropsychopharmacol; 2014 Jun 01; 24(6):846-55. PubMed ID: 24636461
    [Abstract] [Full Text] [Related]

  • 20. An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation.
    Chan HY, Lin AS, Chen KP, Cheng JS, Chen YY, Tsai CJ.
    J Clin Psychopharmacol; 2013 Dec 01; 33(6):747-52. PubMed ID: 24100785
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.